NOV-2018 : Bernard Vrijens, CEO of AARDEX, is an invited speaker at the 2nd value added medicines conference, Brussels, November 21, 2018
This event is organized by Medicines for Europe about ” an innovative approach for patients’ future”.
NOV-2018 : Bernard Vrijens, CEO of AARDEX, is an invited speaker at the 2nd value added medicines conference, Brussels, November 21, 2018
This event is organized by Medicines for Europe about ” an innovative approach for patients’ future”.
In a recent paper titled ‘The impacts of undetected nonadherence in phase II, III and post-marketing clinical trials: An overview’ the authors detailed the findings of a research project which aimed to provide an overview of the consequences of unrecognized
Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance